# The University of New Mexico Cancer Center

Founded by the New Mexico State Legislature (1972)
The Official Cancer Center of the State of New Mexico (2003)
A National Cancer Institute Designated Cancer Center (2005)













## Cheryl L. Willman, MD

The Maurice and Marguerite Liberman Distinguished Chair in Cancer Research
Professor of Pathology and Medicine
Director and CEO, UNM Cancer Center



### **Mission**

To assure that *all* New Mexicans have access to world-class cancer treatment and benefit from advances in cancer research

### The University of New Mexico Cancer Center

will provide outstanding cancer treatment, conduct world-class research to discover the causes and cures for cancer,

train the next generation of cancer healthcare professionals, and overcome New Mexico's significant cancer health disparities through community-based outreach programs.



# UNM Cancer Center: One of The Nation's 66 National Cancer Institute Designated Cancer Centers

### 2005-2010:


Achieved NCI Designation and Federal Funding

#### 2010-2015:

Successful
Competitive Renewal
"Excellent/
Outstanding "

# Fall 2014: Renewal Submission

NCI: Major Source of Federal Funds for Research, Community Programs, New Cancer Treatments



UNM HSC: One of only 38 of the Nation's 126 Medical Schools with an NCI-Designated Cancer Center and a Clinical/Translational Science Center

### FY13 Total Budgeted Revenues \$58.3 Million

**Restricted:** 

\$15,324,455: Restricted Revenues

(Grants with CC Code)

\$58,332,420: Total Research Funding

(NCI Report: UNM, LRRI, SNL, LANL, some NMSU

**Chemistry Collaborations)** 

**Unrestricted:** 

\$34,460,599: Clinical Revenues

\$1,000,000: Development

**Income/Earnings** 

\$5,823,908: State Appropriations

RPSP: \$2,553,000

Cigarette Tax: \$663,120 (1981)

\$2,487,520.00 (2003)

**Tobacco Settlement:** \$135,000

\$1,7384,458: All Other Revenues



### UNM CANCER CENTER GROWTH 2000-2011

Fiscal Year	2000	2003	2007	2009	2010	2011
Total Revenue:	\$8.3 million	\$16.7 million	\$34.8 million	\$59.4 million	\$63.3 million	\$59.9million
Patients Seen:	2,500	5,500	7,600	11,000	15,888	15,742
Ambulatory Clinic Visits:	29,500	53,100	80,600	124,500	137,410	120,578
Chemotherapy Infusions:	3,897	6,089	9,297	11,290	12,335	14,141
Radiation Treatments:	16,235	18,477	18,624	18,801	19,440	16,984
Uncompensated Care:	\$3.5 million	\$3.9 million	\$3.8 million	\$4.9 million	\$5.0 million	\$4.9 million
Board Certified Oncologis	its: 18	24	73	85	85	85
Research Faculty:	59	77	120	125	126	126
Patients from Bernalillo Co	unty: 48%	49%	52 %	52%	57%	56%
Clinical Trial Enrollment:	205	385	553	1,253	1,249	733
Total Research Funding:	\$22.5 million	\$38.9 million	\$51.4 million	\$54.0 million	\$59.1 million	\$60.0 million
Charttable Income:	\$839,184	\$1.5 million	\$2.6 million	\$10.8 million	\$6.3 million	\$2.5 million

### **New Mexico**

# Rich Multiethnic Diversity Distinct Cancer Patterns

Population: 2,220,000
42% Hispanic
10% American Indian
5% Other Minorities
44% Non Hispanic White

### **Tremendous Disparity**

Per Capita Income: 47th

**Poverty: 18 - 36%** 

**Uninsured: 22 - 32%** 

### **Advanced High Technology**

Sandia and Los Alamos National Laboratories UNM Engineering





## **UNM Cancer Center Goals - Research**


 Conduct outstanding trans-disciplinary research in our laboratories, clinics, and multiethnic communities building upon unique institutional and regional scientific strengths and consortium partnerships.

Formal NCI Consortium Partners: Lovelace Respiratory Research
Institute; Sandia National Laboratory; Los Alamos National Laboratory
128 Associated Faculty: \$60M in Annual Peer-Reviewed Funding


 Reduce New Mexico's cancer burden by discovering the genetic, environmental, social, behavioral, and economic factors that contribute to the distinct patterns of cancer incidence, mortality, and disparity in our multiethnic populations.




# Cancer Incidence Rates for the Most Common Sites New Mexico Females, 1997-2006



# Cancer Incidence Rates for the Most Common Sites New Mexico Males, 1997-2006




# **Colorectal Cancer Disparities**



Increasing Colorectal Cancer Incidence in Hispanic Males
NCI P30 CCSG Supplement: Prospective GI Cancer Registry, Community-Based
Research in Etiology, Barriers to Cancer Screening

# Discovery of Novel Clusters and Therapeutic Targets in High Risk ALL: NCI SPECS/TARGET Programs

UNM Cancer Center, St. Jude Children's Research Hospital, COG, NCI TCGA



COG P9906 High-Risk ALL N = 207 COG AALL0232 High-Risk ALL N = 618

Integrated Comprehensive Genomics
Pathways Analysis
Targeted Re-Sequencing
Next Generation Sequencing

*NEJM 360(5):470,2009; Blood 115(18):1394,2010; Blood 115(26):5312,2010; Blood 116:4874,2010* 

# Human Genome Sequencing Discovers Novel Mutations in High Risk ALL / Children of Hispanic and Native American Race / Ethnicity

Library	Known fusions	Putative fusions	Key lesions
HS0825	IGH@-CRLF2		JAK2 R867Q, C20ORF94, CDKN2A
HS1584		EBF1-PDGFRB	IKZF1 (IK6), BTLA-CD200, EBF1, CDKN2A-B
HS1533	IGH@-CRLF2		<b>IKZF1 (IK6),</b> CDKN2A-B, BTG1, C20orf94
HS0897		STRN3-JAK2	IKZF1 deletion and L117fs, BTG1
HS0894		NUP214-ABL1	<b>IKZF1 S402fs,</b> BTLA-CD200, PAX5, CDKN2A-B, C20orf94
HS1534		BCR-JAK2	<b>IKZF1 (IK6),</b> EBF1, PAX5 deletion and G24R, CDKN2A-B, BTG1
HS1537		NONE	EBF1
HS1535		IGH@-EPOR	IKZF1 (e1-5), CDKN2A-B
HS1536		NONE	PAX5, CDKN2A-B, BTG1
HS1576	IGH@-CRLF2		<b>JAK2ins683, IKZF1 (e1-6),</b> BTLA-CD200, EBF1, PAX5 V319fs, CDKN2A-B
SJ		NUP214-ABL1	IKZF1 (IK6), BTG1, NUP-ABL1

## **UNM Cancer Center Goals**

3. Reduce cancer health disparities in New Mexico's multiethnic populations by collaborating with Native American Nations, Pueblos, Hispanic, and urban/rural communities to develop culturally appropriate community-based participatory research, education, screening, and prevention programs.

Office of Community Partnerships and Cancer Health Disparities

4. Translate our novel scientific discoveries into new diagnostic, screening, prevention, and therapeutic clinical trials..




# Community Partnerships for Education, Screening, and Patient Navigation

#### Cancer 101:

Culturally-appropriate cancer education developed at UNM Cancer Center for Hispanic and Native American Communities based on NCI CIS program

#### Since 2005:

- Trained 75 Hispanic Promotoras who have delivered the program to 441 community participants
- Trained 333 Native American
   Community Health Workers (CHWs)
   who take the program back to their
   communities
- Established NACLI: The Native American Cancer Leadership Institute



# Deliver Cancer Screening Services and Patient Navigation Programs

- Mobile Mammography Project (State of NM, ACS, Nancy Floyd Haworth Foundation)
- NM Cancer Care Alliance training of patient navigators
- CDC-funded Breast and Cervical Cancer Detection Program
- Screened 900 women



Mobile Mammography Project Screening Las Vegas, New Mexico; October, 2009







# Cancer Biology & Biotechnology - Consortium Partners Los Alamos, Sandia, and UNM Engineering





- NIH U54MH084690: UNM Center for Molecular Discovery (\$15.5M; Sklar)
  - 1 of 9 NIH Roadmap High Throughput Drug Discovery Centers; 30 Targets; 9 NCI Cancer Centers



- 1 of 10 NIH National Centers for Systems Biology
- Modeling of Cancer Signaling Pathways
- NCI Nanotechnology Alliance
  - U01CA151792: Nanotechnology Platform Partnership: Protocells and VLPs for Nano Therapeutics (\$1.9M; Willman, Brinker)
  - NCI U01CA151792: Integrative Nanoscience and Microsystems Training Grant: (\$1.9 M; Oliver, Datye)
  - NIH NHGRI: 3<sup>rd</sup> Generation Sequencing: The \$1000 Genome (\$2.7M; Edwards)
  - NIH/NSF Minority Training Grants










## **Protocells / VLPs: Targeted Delivery of Cancer Therapeutics**



Jeffrey Brinker, PhD
Natl. Acad. Engineering
Sandia Fellow / UNM Engineering
New Protocell Company









Bryce Chackerian, PhD and David Peabody, PhD
New Nanotechnology Methods for Developing New Vaccines
HPV, HIV, Malaria, Cancer Vaccines
NIH / Gates Foundation Funding; New Company: AgilVax





# The New Mexico Cancer Genome Project High Throughput Human Genome Sequencing



Jeremy Edwards, PhD
National Leader in Technology
for the \$1000 Genome
Harvard U



Scott Ness, PhD
Developing New Genome
Methods / Informatics
Northwestern U

- Initial Support for UNM Cancer Center Genomics Core,
   Bioinformatics, and Biostatistics: State Tobacco Settlement
   Funds
- Plan to Sequence Retrospective Tissue Cohorts from NM Cancer Patients to Discover Underlying Cancer Mutations to Develop Personalized Therapies
- Developing Infrastructure for Clinical Sequencing of Tumors from all Newly Diagnosed Cancer Patients at UNMCC to Develop Personalized Therapies
- Forming Oversight/Governance Board for Ethical, Legal, Social, Community Issues of Project

## **Lung Cancer: LRRI Collaborations**

- UNM Cancer Center diagnoses and treats 200-225 New Mexicans with newly diagnosed lung cancer each year
- Lung cancer is a significant cancer burden in New Mexico; it is
  the 2<sup>nd</sup> most common cancer in NM women (after breast cancer)
  and men (after prostate cancer) and the most common cause of
  cancer-related mortality in men and women
- While causally linked to smoking, New Mexican's may also acquire lung cancer through their involvement in uranium mining and other industrial or laboratory exposures.
- Across the nation and in New Mexico, certain forms of lung cancer are increasingly being diagnosed in younger patients, particularly females, who have never smoked, and the etiology of this form of disease is unknown.

# **Lung Cancer: LRRI Collaborations**

- The UNM CRTC and LRRI have been leaders in the development of new cancer therapies for lung cancer and the development of new therapeutic approaches in clinical trials.
- Genome sequencing has identified new mutations in lung cancers and new and highly effective treatments are being developed; the spectrum of these mutations in New Mexicans is unknown.
- Dr. Steve Belinsky of LRRI is the co-leader of the UNM Cancer Center Lung Cancer Research Program
  - UNM Cancer Center provides tumor tissues and access to patients for LRRI investigators.
  - UNM Cancer Center provides LRRI \$140,000 annually in support of project from state and donor funds, in addition to Tobacco Settlement Funds

## HB315 – Speaker Ben Lujan Memorial

- HB315: \$1 million dollars (citing tobacco settlement funds) dedicated for lung cancer research and prevention.
- Proposal Cancer Center Expansion Request:
  - New Faculty Hires: 1) Physician Lead of Multidisciplinary Lung Cancer Program; 2) Scientific Leader for Lung Cancer in the New Mexico Cancer Genome Project
  - Research Program Infrastructure: Staff and Supplies to Sequence 200 Tumors Annually
  - Lung Cancer Clinical Trials: Support for Early Phase Clinical Trials for Testing New Lung Cancer Treatments
  - Lung Cancer Collaborative Projects with New Mexico
     Universities and Foundations

### **UNM Cancer Center Goals**

- 5. Provide access to outstanding cancer treatment for all New Mexicans through the UNM CC and the UNM Statewide Cancer Care Network, improving access to quality care through partnerships with community health systems and providers.

  State's Largest Team of Cancer Physicians/Specialists: 85


  Providing an Unparalleled Level and Quality of Cancer Care
- 6. Increase access and participation of New Mexicans in cancer clinical investigations and cancer clinical trials, facilitated by a UNM-community statewide collaborative clinical trials network:

  The New Mexico Cancer Care Alliance.



# **UNM Cancer Center Goals: Community Partnership**






- Increase access to quality cancer care statewide
- Reduce cancer health disparities in New Mexico's multiethnic and rural populations through community partnerships
- Provide access to new cancer treatments through a statewide cancer clinical trials network: The New Mexico Cancer Care Alliance

## **UNM Cancer Center Goals – Clinical Care**

- Provide access to an unparalleled level of comprehensive, fully integrated cancer diagnosis and treatment for all New Mexicans
- 85 Oncology specialty physicians (MO, RO, Surgery, GYN, Imaging)
- 308 Clinical Staff (442 Total Staff)
- Providing cancer treatment to 65% of adults and 100% of children affected by cancer in NM
  - FY11: 15,742 patients in >120,000Ambulatory Visits
  - 44% of patients from outside of Bernalillo County
  - 52% of patients were racial / ethnic minorities
  - 14-20% Uninsured
- HSC's Highest Press-Gainey Scores

Cancer Patients Served by County at the UNM Cancer Center FY 2011



## **Goals and Challenges for the Next 5 Years**

### **2015 GOALS:**

- To successfully renew our NCI Designation and increase our federal funding
- 2. To become an NCI Designated **Comprehensive** Cancer Center
- 3. To complete our clinical treatment facility (2<sup>nd</sup>, 4<sup>th</sup> Floors; Food Service)
- 4. To continue to build our statewide cancer care partnership and community health networks

